These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 23580573)
1. Rhythmic control of the ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 in malignant cells. Horiguchi M; Koyanagi S; Hamdan AM; Kakimoto K; Matsunaga N; Yamashita C; Ohdo S Cancer Res; 2013 Apr; 73(8):2639-49. PubMed ID: 23580573 [TBL] [Abstract][Full Text] [Related]
2. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593 [TBL] [Abstract][Full Text] [Related]
3. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways. Meng X; Carlson NR; Dong J; Zhang Y Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025 [TBL] [Abstract][Full Text] [Related]
4. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Li M; Zhang Z; Hill DL; Wang H; Zhang R Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326 [TBL] [Abstract][Full Text] [Related]
6. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800 [TBL] [Abstract][Full Text] [Related]
8. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop. Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750 [TBL] [Abstract][Full Text] [Related]
9. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686 [TBL] [Abstract][Full Text] [Related]
10. Distinct control of PERIOD2 degradation and circadian rhythms by the oncoprotein and ubiquitin ligase MDM2. Liu J; Zou X; Gotoh T; Brown AM; Jiang L; Wisdom EL; Kim JK; Finkielstein CV Sci Signal; 2018 Nov; 11(556):. PubMed ID: 30425162 [TBL] [Abstract][Full Text] [Related]
11. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084 [TBL] [Abstract][Full Text] [Related]
12. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937 [TBL] [Abstract][Full Text] [Related]
14. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Zhou J; Kryczek I; Li S; Li X; Aguilar A; Wei S; Grove S; Vatan L; Yu J; Yan Y; Liao P; Lin H; Li J; Li G; Du W; Wang W; Lang X; Wang W; Wang S; Zou W Nat Immunol; 2021 Apr; 22(4):460-470. PubMed ID: 33767425 [TBL] [Abstract][Full Text] [Related]
15. Expression of Epstein-Barr virus BZLF1 immediate-early protein induces p53 degradation independent of MDM2, leading to repression of p53-mediated transcription. Sato Y; Shirata N; Kudoh A; Iwahori S; Nakayama S; Murata T; Isomura H; Nishiyama Y; Tsurumi T Virology; 2009 May; 388(1):204-11. PubMed ID: 19375142 [TBL] [Abstract][Full Text] [Related]
16. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. Okamoto K; Kitabayashi I; Taya Y Biochem Biophys Res Commun; 2006 Dec; 351(1):216-22. PubMed ID: 17056014 [TBL] [Abstract][Full Text] [Related]
17. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205 [TBL] [Abstract][Full Text] [Related]
18. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions. Ma J; Xue Y; Cui W; Li Y; Zhao Q; Ye W; Zheng J; Cheng Y; Ma Y; Li S; Han T; Miao L; Yao L; Zhang J; Liu W Cancer; 2012 Sep; 118(17):4105-16. PubMed ID: 22907703 [TBL] [Abstract][Full Text] [Related]
19. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Toledo F; Wahl GM Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002 [TBL] [Abstract][Full Text] [Related]
20. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Eischen CM; Alt JR; Wang P Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]